Infusional CMF in Metastatic Breast Cancer
Author Information
Author(s): KJ O'Byrne, ML Koukourakis, MP Saunders, AJ Salisbury, R Isaacs, S Varcoe, M Taylor, TS Ganesan, AL Harris, DC Talbot
Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, The Churchill, Oxford Radcliffe Hospital, Oxford, UK
Hypothesis
The study aimed to evaluate the efficacy and tolerability of a modified 'classical' CMF regimen replacing bolus 5-FU with continuous infusional 5-FU.
Conclusion
Infusional 5-FU can be administered safely and is effective in combination with cyclophosphamide and methotrexate in the treatment of metastatic breast cancer.
Supporting Evidence
- Objective tumour responses were seen in 9 of 25 patients (36%).
- The median overall survival was 10 months.
- Infusional 5-FU was well tolerated with manageable side effects.
- Grade III/IV neutropenia was a significant toxicity observed in some cohorts.
- Responses were seen in all four cohorts of the study.
Takeaway
This study tested a new way to give chemotherapy for breast cancer, and it worked well for many patients.
Methodology
A phase I/II dose-finding study evaluating the combination of infusional 5-FU with cyclophosphamide and methotrexate in 25 patients with metastatic breast cancer.
Potential Biases
Potential bias due to lack of randomization and the open-label design.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Median age of participants was 51 years, with a range from 33 to 69 years, all women with stage IV breast cancer.
Statistical Information
Confidence Interval
95% CI 18-58%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website